Multiple sclerosis market to generate sales of $29.8 bn by 2030: GlobalData
Tolebrutinib is expected to be the leading BTK inhibitor by 2030, with forecasted sales of approximately $2.6B across the 7MM
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.